Monoclonal antibody marks first approved Alzheimer’s treatment in nearly twenty years
Earlier this week, the pharmaceutical companies Biogen and Eisai announced encouraging results from a clinical trial for patients with Alzheimer’s disease: a monoclonal antibody treatment, called lecanemab, reduced cognitive decline by 27% in people with early-stage Alzheimer’s compared with those on a placebo after a year and a half. Outside observers say the trial could …
Monoclonal antibody marks first approved Alzheimer’s treatment in nearly twenty years Read More »
